source
- FDA approves Priovant's Lisraya (brepocitinib) for rare skin disease dermatomyositisThe U.S. Food and Drug Administration has cleared the first oral targeted treatment for dermatomyositis, a rare and disabling skin disorder. The medication, brepocitinib, will be sold under the br…
- Medicare’s G2211 billing code for relationship-based primary care falls short of expectationsThe Medicare G2211 billing code, added in 2024, lets doctors add $16 to each visit when they provide comprehensive, relationship‑based primary care. It was meant to reward the broader set of servic…